Clinical Trial Update: A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]

View source ↗

Summary

Phase 2 trial update for CD11301 in Cutaneous T-Cell Lymphoma (CTCL) assessing safety, efficacy, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• CD11301

Snippet

Sponsor: Galderma R&D | Conditions: Cutaneous T Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-04-08